The seroprevalence of adenoviruses since 20001
Human adenoviruses (Ad) are increasingly used as vaccine vectors, especially after Ad5, Ad26, and ChAdY25 (ChAdOx1) were employed as vectors for SARS-CoV-2 vaccines. So far, more than 116 adenovirus genotypes have been identified, divided into 7 species (A-G). Most adenoviruses do not cause diseases...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2025.2475831 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850139661129744384 |
|---|---|
| author | Lingling Hong Jiashun Li Weikai Zeng Yuhua Li Changfa Yu Shutao Zhao Ling Chen Ying Feng |
| author_facet | Lingling Hong Jiashun Li Weikai Zeng Yuhua Li Changfa Yu Shutao Zhao Ling Chen Ying Feng |
| author_sort | Lingling Hong |
| collection | DOAJ |
| description | Human adenoviruses (Ad) are increasingly used as vaccine vectors, especially after Ad5, Ad26, and ChAdY25 (ChAdOx1) were employed as vectors for SARS-CoV-2 vaccines. So far, more than 116 adenovirus genotypes have been identified, divided into 7 species (A-G). Most adenoviruses do not cause diseases or are mildly pathogenic, with only species B and E leading to acute respiratory infections or conjunctival inflammation and species F causing gastrointestinal infections. Previous studies have shown that the seroprevalence of neutralizing antibodies against adenoviruses can be limiting when applying adenoviral vectors. On the other hand, for highly pathogenic adenoviruses, neutralizing antibodies is beneficial for preventing the diseases caused by these adenoviruses. Here, we summarized the studies on the seroprevalence of adenoviruses, especially adenoviruses that may be utilized as vectors for vaccine and gene therapy. We also analysed possible factors associated with the seroprevalence and neutralizing titres. Given the trend of increasing adenoviral vector application, it is necessary to continue the investigation of the seroprevalence of neutralizing antibodies against adenoviruses in different geographic locations and populations. |
| format | Article |
| id | doaj-art-57334676c7704e95ae021c7afbb79d00 |
| institution | OA Journals |
| issn | 2222-1751 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj-art-57334676c7704e95ae021c7afbb79d002025-08-20T02:30:10ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512025-12-0114110.1080/22221751.2025.2475831The seroprevalence of adenoviruses since 20001Lingling Hong0Jiashun Li1Weikai Zeng2Yuhua Li3Changfa Yu4Shutao Zhao5Ling Chen6Ying Feng7Department of Respiratory and Critical Care Medicine, Huadu District People’s Hospital of Guangzhou, South China Medical University, Guangzhou, People’s Republic of ChinaDepartment of Respiratory and Critical Care Medicine, Huadu District People’s Hospital of Guangzhou, South China Medical University, Guangzhou, People’s Republic of ChinaDepartment of Respiratory and Critical Care Medicine, Huadu District People’s Hospital of Guangzhou, South China Medical University, Guangzhou, People’s Republic of ChinaDepartment of Arboviruse vaccine, National Institutes for Food and Drug Control, Beijing, People’s Republic of ChinaCenter for Infection and Immunity, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, People’s Republic of ChinaDepartment of Respiratory and Critical Care Medicine, Huadu District People’s Hospital of Guangzhou, South China Medical University, Guangzhou, People’s Republic of ChinaGuangzhou National Laboratory, Guangzhou, People’s Republic of ChinaGuangzhou National Laboratory, Guangzhou, People’s Republic of ChinaHuman adenoviruses (Ad) are increasingly used as vaccine vectors, especially after Ad5, Ad26, and ChAdY25 (ChAdOx1) were employed as vectors for SARS-CoV-2 vaccines. So far, more than 116 adenovirus genotypes have been identified, divided into 7 species (A-G). Most adenoviruses do not cause diseases or are mildly pathogenic, with only species B and E leading to acute respiratory infections or conjunctival inflammation and species F causing gastrointestinal infections. Previous studies have shown that the seroprevalence of neutralizing antibodies against adenoviruses can be limiting when applying adenoviral vectors. On the other hand, for highly pathogenic adenoviruses, neutralizing antibodies is beneficial for preventing the diseases caused by these adenoviruses. Here, we summarized the studies on the seroprevalence of adenoviruses, especially adenoviruses that may be utilized as vectors for vaccine and gene therapy. We also analysed possible factors associated with the seroprevalence and neutralizing titres. Given the trend of increasing adenoviral vector application, it is necessary to continue the investigation of the seroprevalence of neutralizing antibodies against adenoviruses in different geographic locations and populations.https://www.tandfonline.com/doi/10.1080/22221751.2025.2475831Adenovirusseroprevalenceneutralizing antibody titresadenovirus vectorpre-existing antibodies |
| spellingShingle | Lingling Hong Jiashun Li Weikai Zeng Yuhua Li Changfa Yu Shutao Zhao Ling Chen Ying Feng The seroprevalence of adenoviruses since 20001 Emerging Microbes and Infections Adenovirus seroprevalence neutralizing antibody titres adenovirus vector pre-existing antibodies |
| title | The seroprevalence of adenoviruses since 20001 |
| title_full | The seroprevalence of adenoviruses since 20001 |
| title_fullStr | The seroprevalence of adenoviruses since 20001 |
| title_full_unstemmed | The seroprevalence of adenoviruses since 20001 |
| title_short | The seroprevalence of adenoviruses since 20001 |
| title_sort | seroprevalence of adenoviruses since 20001 |
| topic | Adenovirus seroprevalence neutralizing antibody titres adenovirus vector pre-existing antibodies |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2025.2475831 |
| work_keys_str_mv | AT linglinghong theseroprevalenceofadenovirusessince20001 AT jiashunli theseroprevalenceofadenovirusessince20001 AT weikaizeng theseroprevalenceofadenovirusessince20001 AT yuhuali theseroprevalenceofadenovirusessince20001 AT changfayu theseroprevalenceofadenovirusessince20001 AT shutaozhao theseroprevalenceofadenovirusessince20001 AT lingchen theseroprevalenceofadenovirusessince20001 AT yingfeng theseroprevalenceofadenovirusessince20001 AT linglinghong seroprevalenceofadenovirusessince20001 AT jiashunli seroprevalenceofadenovirusessince20001 AT weikaizeng seroprevalenceofadenovirusessince20001 AT yuhuali seroprevalenceofadenovirusessince20001 AT changfayu seroprevalenceofadenovirusessince20001 AT shutaozhao seroprevalenceofadenovirusessince20001 AT lingchen seroprevalenceofadenovirusessince20001 AT yingfeng seroprevalenceofadenovirusessince20001 |